Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.
about
Ovarian carcinoma subtypes are different diseases: implications for biomarker studiesSex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data.Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers.Genetic analysis of the early natural history of epithelial ovarian carcinomaOvarian cancer: linking genomics to new target discovery and molecular markers--the way ahead.Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistryUnpacking the blockers: understanding perceptions and social constraints of health communication in hereditary breast ovarian cancer (HBOC) susceptibility familiesBRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.Critical molecular abnormalities in high-grade serous carcinoma of the ovary.The impact of germline mutations on targeted therapy.Cell surface protein glycosylation in cancer.ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?Early adoption of BRCA1/2 testing: who and why.Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene.Familial invasive and borderline ovarian tumors by proband status, age and histology.Molecular analysis of peritoneal fluid in ovarian cancer patients.Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred.
P2860
Q21563402-23082EF5-5889-4AAB-9352-87BB6E0BE46AQ30983330-F6F9CE83-9A53-48E6-9B02-93D512B5B157Q33206391-3DF7377F-A241-4D59-93BB-A922D645EDD6Q33570452-FE64BB81-A2B2-4150-A020-089B1A0D6A65Q33748323-3FC503DA-36D3-4CA5-B547-902CB855D362Q34442933-1B5D94E0-C993-41CF-9FE6-FBA5E3C55FBFQ36141992-1D10BD9D-4B9A-477D-AFD8-E13DE7C60801Q36696220-5C5EBBB0-038F-43A5-95D1-EEF136A432DEQ37232123-C8ECB337-CF18-4849-A48E-28286B069C23Q38151546-7D084FFF-DDB3-4BAF-AF9E-2F1BC3FC2D62Q38171440-9F5A539B-9F19-4E43-8B70-D4B6BF9446BCQ38719990-56857212-DDAE-486F-8927-74C864DD8DAFQ38868393-D39F4F02-FFB8-434F-898A-C9CD088E8C48Q40599508-7080110F-4478-4B75-B582-F27F47AA1C10Q45174307-77FAF512-3207-454F-A7B3-19966E971FAAQ47921543-BA3E4F4F-FFF6-4058-B129-418B4EF4F76DQ54764570-37474992-F863-48BA-8D74-679DA8C1329FQ55615119-327DDD6F-998E-4AB7-BF08-2321C2EBB965
P2860
Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Current understanding of the e ...... mutations for ovarian cancer.
@ast
Current understanding of the e ...... mutations for ovarian cancer.
@en
Current understanding of the e ...... mutations for ovarian cancer.
@nl
type
label
Current understanding of the e ...... mutations for ovarian cancer.
@ast
Current understanding of the e ...... mutations for ovarian cancer.
@en
Current understanding of the e ...... mutations for ovarian cancer.
@nl
prefLabel
Current understanding of the e ...... mutations for ovarian cancer.
@ast
Current understanding of the e ...... mutations for ovarian cancer.
@en
Current understanding of the e ...... mutations for ovarian cancer.
@nl
P1476
Current understanding of the e ...... mutations for ovarian cancer.
@en
P2093
P356
10.1097/00001703-200202000-00004
P577
2002-02-01T00:00:00Z